Literature DB >> 21555766

Characteristic resistance mechanism of Mycobacterium tuberculosis to DC-159a, a new respiratory quinolone.

Jun-ichiro Sekiguchi1, Areeya Disratthakit, Shinji Maeda, Norio Doi.   

Abstract

A G88C mutation in GyrA is one of the key alterations by which Mycobacterium tuberculosis mutants acquire DC-159a resistance in vitro. A novel double mutation in GyrA, G88C D94H, conferred high DC-159a resistance. Different mutation patterns in GyrA were demonstrated for DC-159a-resistant mutants and quinolone-resistant multidrug-resistant (QR-MDR) M. tuberculosis isolates, with a mutation either at position 90 or 94 and double mutations at 90 and 91 or at 90 and 94. DC-159a might be promising for QR M. tuberculosis treatment.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21555766      PMCID： PMC3147633          DOI： 10.1128/AAC.00417-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  Daniel E Rozen; Lesley McGee; Bruce R Levin; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand.

Authors:  Pannamthip Pitaksajjakul; Waranya Wongwit; Wantanee Punprasit; Boonchuy Eampokalap; Sharon Peacock; Pongrama Ramasoota
Journal:  Southeast Asian J Trop Med Public Health       Date:  2005       Impact factor: 0.267

3.  Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones.

Authors:  Stéphanie Matrat; Nicolas Veziris; Claudine Mayer; Vincent Jarlier; Chantal Truffot-Pernot; Juliette Camuset; Elisabeth Bouvet; Emmanuelle Cambau; Alexandra Aubry
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

4.  In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.

Authors:  Areeya Disratthakit; Norio Doi
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

5.  Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology.

Authors:  J D van Embden; M D Cave; J T Crawford; J W Dale; K D Eisenach; B Gicquel; P Hermans; C Martin; R McAdam; T M Shinnick
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

6.  Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in North India.

Authors:  Noman Siddiqi; Mohammed Shamim; Seema Hussain; Rakesh Kumar Choudhary; Niyaz Ahmed; Sharmistha Banerjee; G R Savithri; Mahfooz Alam; Niteen Pathak; Amol Amin; Mohammed Hanief; V M Katoch; S K Sharma; Seyed E Hasnain
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

7.  Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis.

Authors:  Y Onodera; M Tanaka; K Sato
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

8.  Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.

Authors:  J C Rodríguez; L Cebrián; M López; M Ruiz; I Jiménez; G Royo
Journal:  J Antimicrob Chemother       Date:  2004-02-12       Impact factor: 5.790

9.  Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.

Authors:  Augustine F B Cheng; Wing W Yew; Edward W C Chan; Miu L Chin; Mamie M M Hui; Raphael C Y Chan
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

Review 10.  Emerging mechanisms of fluoroquinolone resistance.

Authors:  D C Hooper
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883
View more
  4 in total

1.  Potent in vitro antibacterial activity of DS-8587, a novel broad-spectrum quinolone, against Acinetobacter baumannii.

Authors:  Saito Higuchi; Yoshikuni Onodera; Megumi Chiba; Kazuki Hoshino; Naomasa Gotoh
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

2.  Moxifloxacin retains antimycobacterial activity in the presence of gyrA mutations.

Authors:  Marieta McGrath; Nico C Gey van Pittius; Frederick A Sirgel; Paul D Van Helden; Robin M Warren
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

Review 3.  Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review.

Authors:  Elisea Avalos; Donald Catanzaro; Antonino Catanzaro; Theodore Ganiats; Stephanie Brodine; John Alcaraz; Timothy Rodwell
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

Review 4.  Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review.

Authors:  Klaudia T Angula; Lesetja J Legoabe; Richard M Beteck
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.